Patents Assigned to Aventis Pharmaceuticals Inc.
  • Benzimidazoles
    Publication number: 20060014756
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Application
    Filed: January 4, 2005
    Publication date: January 19, 2006
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Michael Edwards, Paul Cox, Shelley Amendola, Stephanie Deprets, Timothy Gillespy, Christopher Edlin, Andrew Morley, Charles Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir Majid, John Reader, Lloyd Payne, Nawaz Khan, Michael Cherry
  • Method and system for marketing a treatment regimen
    Publication number: 20050283386
    Abstract: A software program, for use on a computing device such as a Personal Digital Assistant (PDA) device, is provided to a health care provider (HCP). The software program configures the computing device with means for inputting profile information regarding patients and means for comparing the patient profile information against a database containing information regarding one or more drug studies performed on patients having similar medical histories and/or symptoms. The patient information is compared against the database, and, where appropriate, the healthcare provider is made aware that the patient associated with the patient profile could benefit from being prescribed to take the drug or drugs on which the study is based, and/or at a particular dose indicated by the study.
    Type: Application
    Filed: November 20, 2003
    Publication date: December 22, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Joseph Powers, William Rehm, Carla Letourneau, Danny Pendleton, Stephen Lahaye
  • Compounds and compositions as cathepsin S inhibitors
    Patent number: 6977256
    Abstract: The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: December 20, 2005
    Assignees: Aventis Pharmaceuticals Inc., Axys Pharmaceuticals, Inc.
    Inventors: Jiayo Li, David J. Aldous, Sukanthini Thurairatnam
  • Chemical compounds
    Patent number: 6977263
    Abstract: Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: December 20, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Peter C. Astles, Paul R. Eastwood, Olivier Houille, Julian Levell, Heinz Pauls, Mark Czekaj, Guyan Liang, Yong Gong, James Pribish, Kent Neuenschwander
  • Use of R (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-flurophenyl)-ethyl]-4- piperidinemethanol for the treatment of sleep disorders and process for making pharmaceutical composition
    Publication number: 20050272773
    Abstract: A process for making a pharmaceutical composition for treating a variety of sleep disorders comprising an effective amount of R-(+)-?-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof is disclosed and claimed.
    Type: Application
    Filed: June 10, 2005
    Publication date: December 8, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Cesar Mondadori, Stephen Sorensen, Janice Hitchcock
  • Azaindoles
    Publication number: 20050267304
    Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Application
    Filed: November 23, 2004
    Publication date: December 1, 2005
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Paul Cox, Tahir Majid, Justine Lai, Andrew Morley, Shelley Amendola, Stephanie Deprets, Christopher Edlin, Charles Gardner, Dorothea Kominos, Brian Pedgrift, Frank Halley, Timothy Gillespy, Michael Edwards, Francois Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel Bezard, Chantal Carrez
  • Novel compounds and compositions as cathepsin S inhibitors
    Publication number: 20050267044
    Abstract: The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
    Type: Application
    Filed: June 24, 2005
    Publication date: December 1, 2005
    Applicants: Aventis Pharmaceuticals Inc., Axys Pharmaceuticals, Inc.
    Inventors: Jiayo Li, David Aldous, Sukanthini Thurairatnam
  • Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
    Publication number: 20050261341
    Abstract: The present invention provides various processes for the preparation of (R)-?-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.
    Type: Application
    Filed: April 26, 2005
    Publication date: November 24, 2005
    Applicants: Aventis Pharmaceuticals Inc., Aventis Pharma Deutschland GmbH
    Inventors: Wolfgang Laux, Gerard Guillamot, Frederick Laskovics, Chi-Hsin King, James Hitt, Sandra Stolz-Dunn, Ian Tomlinson, Johannes Koek
  • Method of treating of demyelinating diseases or conditions
    Patent number: 6967210
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: November 22, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
  • Novel 4-diphenylmethyl piperidine derivatives
    Publication number: 20050239834
    Abstract: This invention relates to novel substituted piperidine derivatives. More particularly, this invention relates to substituted phenyl 4-substituted-piperidinoalkanol derivatives which are useful as antihistamines, antiallergy agents and bronchodilators.
    Type: Application
    Filed: June 9, 2005
    Publication date: October 27, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Kah Ling, Paul Brown, Robert Strom, Richard Wolf
  • Method of treating of demyelinating diseases or conditions
    Publication number: 20050234105
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Application
    Filed: March 14, 2005
    Publication date: October 20, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Craig Smith, Michel Rathbone, Margaret Petty, David Rampe
  • Chemical compounds
    Publication number: 20050228018
    Abstract: Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.
    Type: Application
    Filed: February 14, 2005
    Publication date: October 13, 2005
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Peter Astles, Paul Eastwood, Olivier Houille, Julian Levell, Heinz Pauls, Mark Czekaj, Guyan Liang, Yong Gong, James Pribish, Kent Neuenschwander
  • 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
    Patent number: 6953788
    Abstract: The present invention relates to certain novel 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase. Pharmaceutical compositions containing said compounds as well as methods of treating various disease states responding to inhibition of matrix metalloproteinase are also claimed herein.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: October 11, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Alan M. Warshawsky, Joseph T. Tsay, Michael J. Janusz, Jian Shen, Gary A. Flynn, Ramalinga M. Dharanipragada, Joseph P. Burkhart, Douglas W. Beight, Meena V. Patel
  • Interactive electronic-desktop alert and compliance tool
    Publication number: 20050197903
    Abstract: The present invention improves upon tools of the prior art by enabling a user of such a tool to have alerts sent to an electronic “desktop” of multiple devices, such as a computer screen, the display of a Personal Digital Assistant (PDA) or cell phone, pagers and the like. Further, in accordance with the present invention, the user of the tool is solicited to provide information back to the tool. This interactive aspect can take on many forms and can be used for marketing and or and/or medical research, and can also be used to give the user positive reinforcement for compliant behavior; for example, when the user takes the appropriate dosage of a medication at the appropriate time, the tool's graphics could respond by displaying a positive graphic such as a smiling face. Failure to properly follow a medication regimen could result in the display of a negative graphic, such as a said face.
    Type: Application
    Filed: January 7, 2005
    Publication date: September 8, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Daniel Hoffman, Michael Sutch, Jamie O'Keefe, William Rehm
  • Use of R (+)-?-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
    Patent number: 6939879
    Abstract: A method of providing symptomatic relief from sleep induced insomnia in a patient comprising administering an effective amount of R-(+)-?-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: September 6, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Cesare Mondadori, Stephen M. Sorensen, Janice M. Hitchcock
  • Oxydecahydronaphthalene modulators of HM74
    Publication number: 20050187263
    Abstract: Host cells expressing HM74 were used to obtain oxydecalin-like molecules with agonist activity having the following structure:
    Type: Application
    Filed: February 14, 2005
    Publication date: August 25, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Anne Minnich, Theresa Kuntzweiler, Haifeng Eishingdrelo, Michael Angelastro, Stephan Henke
  • Furosemide modulators of HM74
    Publication number: 20050187280
    Abstract: Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula:
    Type: Application
    Filed: February 14, 2005
    Publication date: August 25, 2005
    Applicants: Aventis Pharmaceuticals Inc., Aventis Pharma Deutschland GmbH
    Inventors: Anne Minnich, Theresa Kuntzweiler, Haifeng Eishingdrelo, Michael Angelastro, Hans-Jochen Lang
  • Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
    Publication number: 20050182054
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Application
    Filed: January 25, 2005
    Publication date: August 18, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Michael Myers, Alfred Spada, Paul Persons, Martin Maguire
  • Antihistaminic piperidine derivatives and intermediates for the preparation thereof
    Patent number: 6930197
    Abstract: This invention relates to a process for the preparation of compounds of the formula: wherein R1 is C1-C6alkyl and the C1-C6alkyl moiety is straight or branched.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: August 16, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventor: Timothy A. Ayers
  • Dissolution test sample holder
    Patent number: 6929782
    Abstract: A dissolution test sample holder for testing topical formulations for dermal and/or transdermal drug delivery is disclosed. The holder has a cylinder tubular body with an end cap removably attached to one end. The end cap has a peripheral wall which frictionally engages the body to hold the end cap in place. A flange extends perpendicularly from the peripheral wall inwardly defining an aperture in the end cap and providing a support surface for a membrane held within the end cap. A ring is positioned within the end cap on the membrane, the membrane being sandwiched between the ring and the support surface. The ring protects the membrane by preventing contact between it and the body and provides a volume for holding the test sample in contact with the membrane.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: August 16, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Cynthia M. Ciliberto, Kenneth M. Feld, Donna M. Heren